Search Results - "Horga, A."

Brainstem lesions in clinically isolated syndromes by TINTORE, M, ROVIRA, A, PEREZ-MIRALLES, F, HUERGA, E, COMABELLA, M, SASTRE-GARRIGA, J, MONTALBAN, X, ARRAMBIDE, G, MITJANA, R, RIO, J, AUGER, C, NOS, C, EDO, M. C, CASTILLO, J, HORGA, A

“…Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS). To investigate the role of baseline…”
Get full text

Measures in the first year of therapy predict the response to interferon β in MS by Río, J, Castilló, J, Rovira, A, Tintoré, M, Sastre-Garriga, J, Horga, A, Nos, C, Comabella, M, Aymerich, X, Montalbán, X

“…Background and objective Several criteria for treatment response to interferon beta (IFNβ) have been proposed, although there is no consensus among different…”
Get full text

Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months by LLUFRIU, S, CASTILLO, J, GRAUS, F, MONTALBAN, X, SAIZ, A, BLANCO, Y, RAMIO-TORRENTA, L, RIO, J, VALLES, M, LOZANO, M, CASTELLA, M. D, CALABIA, J, HORGA, A

“…Plasma exchange (PE) is used to treat severe episodes of CNS demyelination unresponsive to corticosteroids. Predictors of long-term response are not well…”
Get full text

Clinical impact of early brain atrophy in clinically isolated syndromes by Pérez-Miralles, F, Sastre-Garriga, J, Tintoré, M, Arrambide, G, Nos, C, Perkal, H, Río, J, Edo, MC, Horga, A, Castilló, J, Auger, C, Huerga, E, Rovira, A, Montalban, X

“…Background: The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not…”
Get full text

Post-COVID symptoms of potential peripheral nervous and muscular origin by Silva-Hernández, L., Cabal-Paz, B., Mayo-Canalejo, D., Horga, A.

“…Many patients report persistent symptoms attributable to dysfunction of the peripheral nervous and muscular systems after acute COVID-19. These symptoms may…”
Get full text

A Homozygous Reticulon 2 mutation is a cause of DHMN with pyramidal signs by Rossor, A.M, Rebelo, A, Horga, A, Tomaselli, P.J, Gonzalez, M, Zuchner, S, Reilly, M.M

Get full text

Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis by Cantó, E, Reverter, F, Morcillo-Suárez, C, Matesanz, F, Fernández, O, Izquierdo, G, Vandenbroeck, K, Rodríguez-Antigüedad, A, Urcelay, E, Arroyo, R, Otaegui, D, Olascoaga, J, Saiz, A, Navarro, A, Sanchez, A, Domínguez, C, Caminero, A, Horga, A, Tintoré, M, Montalban, X, Comabella, M

“…Background: Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in…”
Get full text

Nivolumab: An “immune storm” in a patient with history of myasthenia gravis by Montalvo Moraleda, T., Horga, A., Galán Dávila, L., Guerrero Sola, A., Silva Hernández, L.

Get full text

Cause of death in a cohort of mitochondrial patients by Skorupinska, I, Bugiardini, E, Ng, Y.S, Horga, A, Poole, O.V, McFarland, R, Pitceathly, R.D.S, Turnbull, D.M, Hanna, M.G

Get full text

Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? by Pelayo, R., Montalban, X., Minoves, T., Moncho, D., Rio, J., Nos, C., Tur, C., Castillo, J., Horga, A., Comabella, M., Perkal, H., Rovira, A., Tintoré, M.

“…The role of multimodal evoked potentials (MMEPs) in establishing multiple sclerosis (MS) diagnosis and prognosis has diminished nowadays. The objective of this…”
Get full text

Value of NMO-IgG determination at the time of presentation as CIS by COSTA, C, ARRAMBIDE, G, NOS, C, ROVIRA, A, COMABELLA, M, HORGA, A, MONTALBAN, X, TINTORE, M, CASTILLO, J, SASTRE-GARRIGA, J, TUR, C, RIO, J, SAIZ, A, VIDAL-JORDANA, A, AUGER, C

“…Despite the availability of diagnostic criteria, an overlap between neuromyelitis optica (NMO) and multiple sclerosis (MS) exists, particularly in the early…”
Get full text

Natalizumab for relapsing-remitting multiple sclerosis by Horga, A, Tintoré, M

“…Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of…”
Get more information

Nivolumab: An «Immune storm» in a patient with history of myasthenia gravis by Montalvo Moraleda, T, Horga, A, Galán Dávila, L, Guerrero Sola, A, Silva Hernández, L

Get full text

Nivolumab: «Tormenta inmune» en paciente con miastenia gravis previa by Montalvo Moraleda, T., Horga, A., Galán Dávila, L., Guerrero Sola, A., Silva Hernández, L.

Get full text

P25 Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis (HYP HOP trial) by Burge, J, Horga, A, Griggs, R.C, Hanna, M.G

Get full text

1212 EXPOSURE-RESPONSE ANALYSES OF PEGYLATED INTERFERON LAMBDA (LAMBDA, BMS-914143) IN PATIENTS WITH CHRONIC HCV INFECTION: DOSE SELECTION FOR PHASE 3 CLINICAL TRIALS by Wang, X, Chan, P, Ahmad, A, Freeman, J, Horga, A, Hillson, J, Lopez-Talavera, J.C, Kansra, V

Get full text

Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS by Sastre-Garriga, Jaume, Tintoré, M., Nos, C., Tur, C., Río, J., Téllez, N., Castilló, J., Horga, A., Perkal, H., Comabella, M., Rovira, A., Montalban, X.

“…Recognition of multiple sclerosis (MS) attacks relies mostly on clinical assessment. However, their definition based on McDonald criteria refers mostly to…”
Get full text

P56 Whole-exome sequencing in patients with sensory and motor inherited neuropathies by Horga, A, Cottenie, E, Liu, Y-T, Pandraud, A, Rossor, A.M, Pitceathly, R.D.S, Laurá, M, Hanna, M.G, Houlden, H, Reilly, M.M

Get full text

Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation by Peiró, A.M., Climent, L., Zapater, P., Horga, A., Horga, J.F.

“…How can we treat patients with reduced morphine doses without loosing the pain killing effect or morphine antinociceptive effects (MAE)? To address this…”
Get full text

Antiviral immune response in patients with multiple sclerosis and healthy siblings by Comabella, M., Montalban, X., Horga, A., Messmer, B., Kakalacheva, K., Strowig, T., Caballero, E., Münz, C., Lünemann, JD

“…The objective of this study was to determine the immune responses to candidate viral triggers of multiple sclerosis in patients and healthy siblings raised in…”
Get full text